Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 for moderate-to-severe chronic obstructive pulmonary disease
CTR20242775Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in chronic obstructive pulmonary disease (COPD), sponsored by Keymed Biosciences. Started Jul 2024; status: active.
02
Drugs
stapokibart
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20242775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242775.